APO Research
Talk to an analyst

APO RESEARCH · REPORT

Autoimmune and Inflammatory Immunomodulators

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Autoimmune and Inflammatory Immunomodulators Market Outlook and Growth Opportunities 2026

19 December 2025195 pages

Choose your research edition.

Industry ResearchAutoimmune and Inflammatory Immunomodulators Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Autoimmune and Inflammatory Immunomodulators Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Autoimmune and Inflammatory Immunomodulators Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Autoimmune and Inflammatory Immunomodulators Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Autoimmune and Inflammatory Immunomodulators Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Autoimmune and Inflammatory Immunomodulators market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Autoimmune and Inflammatory Immunomodulators is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Autoimmune and Inflammatory Immunomodulators is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Autoimmune and Inflammatory Immunomodulators is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Autoimmune and Inflammatory Immunomodulators market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Autoimmune and Inflammatory Immunomodulators market include Johnson & Johnson, Eli Lilly, Pfizer, Amgen, AbbVie, AstraZeneca, Gilead Sciences, F. Hoffmann-La Roche and Enlivex Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Autoimmune and Inflammatory Immunomodulators market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Autoimmune and Inflammatory Immunomodulators and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Autoimmune and Inflammatory Immunomodulators sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Autoimmune and Inflammatory Immunomodulators market size, projected growth trends, production technologies, key applications, and end-use industries.

Autoimmune and Inflammatory Immunomodulators Segment by Company

Johnson & Johnson

Eli Lilly

Pfizer

Amgen

AbbVie

AstraZeneca

Gilead Sciences

F. Hoffmann-La Roche

Enlivex Therapeutics

Bristol-Myers Squibb

Boehringer Ingelheim

Biogen Idec

Avaxia Biologics

Autoimmune and Inflammatory Immunomodulators Segment by Type

Biologics

Small Molecules

Autoimmune and Inflammatory Immunomodulators Segment by Application

Rheumatoid Arthritis

IBD

Autoimmune and Inflammatory Immunomodulators Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Autoimmune and Inflammatory Immunomodulators status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Autoimmune and Inflammatory Immunomodulators market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Autoimmune and Inflammatory Immunomodulators significant trends, drivers, influence factors in global and regions.

6. To analyze Autoimmune and Inflammatory Immunomodulators competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Autoimmune and Inflammatory Immunomodulators market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Autoimmune and Inflammatory Immunomodulators and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Autoimmune and Inflammatory Immunomodulators.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Autoimmune and Inflammatory Immunomodulators market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Autoimmune and Inflammatory Immunomodulators industry.

Chapter 3: Detailed analysis of Autoimmune and Inflammatory Immunomodulators manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Autoimmune and Inflammatory Immunomodulators in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Autoimmune and Inflammatory Immunomodulators in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Autoimmune and Inflammatory Immunomodulators Industry Trends Table 2. Autoimmune and Inflammatory Immunomodulators Industry Drivers Table 3. Autoimmune and Inflammatory Immunomodulators Industry Opportunities and Challenges Table 4. Autoimmune and Inflammatory Immunomodulators Industry Restraints Table 5. Global Autoimmune and Inflammatory Immunomodulators Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Autoimmune and Inflammatory Immunomodulators Revenue Share by Company (2021-2026) Table 7. Global Autoimmune and Inflammatory Immunomodulators Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Autoimmune and Inflammatory Immunomodulators Sales Volume Share by Company (2021-2026) Table 9. Global Autoimmune and Inflammatory Immunomodulators Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Autoimmune and Inflammatory Immunomodulators Company Ranking, (2024-2026) & (USD Million) Table 11. Global Autoimmune and Inflammatory Immunomodulators Key Company Manufacturing Base & Headquarters Table 12. Global Autoimmune and Inflammatory Immunomodulators Company, Product Type & Application Table 13. Global Autoimmune and Inflammatory Immunomodulators Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Autoimmune and Inflammatory Immunomodulators by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Biologics Table 18. Significant Companies of Small Molecules Table 19. Global Autoimmune and Inflammatory Immunomodulators Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 20. Global Autoimmune and Inflammatory Immunomodulators Sales Volume by Type (2021-2026) & (W Units) Table 21. Global Autoimmune and Inflammatory Immunomodulators Sales Volume by Type (2027-2032) & (W Units) Table 22. Global Autoimmune and Inflammatory Immunomodulators Sales Volume Share by Type (2021-2026) Table 23. Global Autoimmune and Inflammatory Immunomodulators Sales Volume Share by Type (2027-2032) Table 24. Global Autoimmune and Inflammatory Immunomodulators Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Autoimmune and Inflammatory Immunomodulators Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Autoimmune and Inflammatory Immunomodulators Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type (2021-2026) Table 28. Global Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Rheumatoid Arthritis Table 30. Significant Companies of IBD Table 31. Global Autoimmune and Inflammatory Immunomodulators Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 32. Global Autoimmune and Inflammatory Immunomodulators Sales Volume by Application (2021-2026) & (W Units) Table 33. Global Autoimmune and Inflammatory Immunomodulators Sales Volume by Application (2027-2032) & (W Units) Table 34. Global Autoimmune and Inflammatory Immunomodulators Sales Volume Share by Application (2021-2026) Table 35. Global Autoimmune and Inflammatory Immunomodulators Sales Volume Share by Application (2027-2032) Table 36. Global Autoimmune and Inflammatory Immunomodulators Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Autoimmune and Inflammatory Immunomodulators Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Autoimmune and Inflammatory Immunomodulators Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application (2021-2026) Table 40. Global Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application (2027-2032) Table 41. Global Autoimmune and Inflammatory Immunomodulators Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 42. Global Autoimmune and Inflammatory Immunomodulators Sales by Region (2021-2026) & (W Units) Table 43. Global Autoimmune and Inflammatory Immunomodulators Sales Market Share by Region (2021-2026) Table 44. Global Autoimmune and Inflammatory Immunomodulators Sales by Region (2027-2032) & (W Units) Table 45. Global Autoimmune and Inflammatory Immunomodulators Sales Market Share by Region (2027-2032) Table 46. Global Autoimmune and Inflammatory Immunomodulators Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Autoimmune and Inflammatory Immunomodulators Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Autoimmune and Inflammatory Immunomodulators Sales Value Share by Region (2021-2026) Table 49. Global Autoimmune and Inflammatory Immunomodulators Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Autoimmune and Inflammatory Immunomodulators Sales Value Share by Region (2027-2032) Table 51. Global Autoimmune and Inflammatory Immunomodulators Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Autoimmune and Inflammatory Immunomodulators Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Autoimmune and Inflammatory Immunomodulators Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 54. Global Autoimmune and Inflammatory Immunomodulators Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Autoimmune and Inflammatory Immunomodulators Sales by Country (2021-2026) & (W Units) Table 56. Global Autoimmune and Inflammatory Immunomodulators Sales Market Share by Country (2021-2026) Table 57. Global Autoimmune and Inflammatory Immunomodulators Sales by Country (2027-2032) & (W Units) Table 58. Global Autoimmune and Inflammatory Immunomodulators Sales Market Share by Country (2027-2032) Table 59. Global Autoimmune and Inflammatory Immunomodulators Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Autoimmune and Inflammatory Immunomodulators Sales Value Market Share by Country (2021-2026) Table 61. Global Autoimmune and Inflammatory Immunomodulators Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Autoimmune and Inflammatory Immunomodulators Sales Value Market Share by Country (2027-2032) Table 63. Johnson & Johnson Company Information Table 64. Johnson & Johnson Business Overview Table 65. Johnson & Johnson Autoimmune and Inflammatory Immunomodulators Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Johnson & Johnson Autoimmune and Inflammatory Immunomodulators Product Portfolio Table 67. Johnson & Johnson Recent Development Table 68. Eli Lilly Company Information Table 69. Eli Lilly Business Overview Table 70. Eli Lilly Autoimmune and Inflammatory Immunomodulators Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Eli Lilly Autoimmune and Inflammatory Immunomodulators Product Portfolio Table 72. Eli Lilly Recent Development Table 73. Pfizer Company Information Table 74. Pfizer Business Overview Table 75. Pfizer Autoimmune and Inflammatory Immunomodulators Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Pfizer Autoimmune and Inflammatory Immunomodulators Product Portfolio Table 77. Pfizer Recent Development Table 78. Amgen Company Information Table 79. Amgen Business Overview Table 80. Amgen Autoimmune and Inflammatory Immunomodulators Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Amgen Autoimmune and Inflammatory Immunomodulators Product Portfolio Table 82. Amgen Recent Development Table 83. AbbVie Company Information Table 84. AbbVie Business Overview Table 85. AbbVie Autoimmune and Inflammatory Immunomodulators Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. AbbVie Autoimmune and Inflammatory Immunomodulators Product Portfolio Table 87. AbbVie Recent Development Table 88. AstraZeneca Company Information Table 89. AstraZeneca Business Overview Table 90. AstraZeneca Autoimmune and Inflammatory Immunomodulators Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. AstraZeneca Autoimmune and Inflammatory Immunomodulators Product Portfolio Table 92. AstraZeneca Recent Development Table 93. Gilead Sciences Company Information Table 94. Gilead Sciences Business Overview Table 95. Gilead Sciences Autoimmune and Inflammatory Immunomodulators Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Gilead Sciences Autoimmune and Inflammatory Immunomodulators Product Portfolio Table 97. Gilead Sciences Recent Development Table 98. F. Hoffmann-La Roche Company Information Table 99. F. Hoffmann-La Roche Business Overview Table 100. F. Hoffmann-La Roche Autoimmune and Inflammatory Immunomodulators Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. F. Hoffmann-La Roche Autoimmune and Inflammatory Immunomodulators Product Portfolio Table 102. F. Hoffmann-La Roche Recent Development Table 103. Enlivex Therapeutics Company Information Table 104. Enlivex Therapeutics Business Overview Table 105. Enlivex Therapeutics Autoimmune and Inflammatory Immunomodulators Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Enlivex Therapeutics Autoimmune and Inflammatory Immunomodulators Product Portfolio Table 107. Enlivex Therapeutics Recent Development Table 108. Bristol-Myers Squibb Company Information Table 109. Bristol-Myers Squibb Business Overview Table 110. Bristol-Myers Squibb Autoimmune and Inflammatory Immunomodulators Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Bristol-Myers Squibb Autoimmune and Inflammatory Immunomodulators Product Portfolio Table 112. Bristol-Myers Squibb Recent Development Table 113. Boehringer Ingelheim Company Information Table 114. Boehringer Ingelheim Business Overview Table 115. Boehringer Ingelheim Autoimmune and Inflammatory Immunomodulators Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Boehringer Ingelheim Autoimmune and Inflammatory Immunomodulators Product Portfolio Table 117. Boehringer Ingelheim Recent Development Table 118. Biogen Idec Company Information Table 119. Biogen Idec Business Overview Table 120. Biogen Idec Autoimmune and Inflammatory Immunomodulators Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Biogen Idec Autoimmune and Inflammatory Immunomodulators Product Portfolio Table 122. Biogen Idec Recent Development Table 123. Avaxia Biologics Company Information Table 124. Avaxia Biologics Business Overview Table 125. Avaxia Biologics Autoimmune and Inflammatory Immunomodulators Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Avaxia Biologics Autoimmune and Inflammatory Immunomodulators Product Portfolio Table 127. Avaxia Biologics Recent Development Table 128. Key Raw Materials Table 129. Raw Materials Key Suppliers Table 130. Autoimmune and Inflammatory Immunomodulators Distributors List Table 131. Autoimmune and Inflammatory Immunomodulators Customers List Table 132. Research Programs/Design for This Report Table 133. Authors List of This Report Table 134. Secondary Sources Table 135. Primary Sources List of Figures Figure 1. Autoimmune and Inflammatory Immunomodulators Product Image Figure 2. Global Autoimmune and Inflammatory Immunomodulators Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Autoimmune and Inflammatory Immunomodulators Sales Value (2021-2032) & (US$ Million) Figure 4. Global Autoimmune and Inflammatory Immunomodulators Sales (2021-2032) & (W Units) Figure 5. Global Autoimmune and Inflammatory Immunomodulators Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Autoimmune and Inflammatory Immunomodulators Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Biologics Image Figure 10. Small Molecules Image Figure 11. Global Autoimmune and Inflammatory Immunomodulators Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 12. Global Autoimmune and Inflammatory Immunomodulators Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Autoimmune and Inflammatory Immunomodulators Sales Volume Share by Type (2021-2032) Figure 14. Global Autoimmune and Inflammatory Immunomodulators Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Autoimmune and Inflammatory Immunomodulators Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type (2021-2032) Figure 17. Rheumatoid Arthritis Image Figure 18. IBD Image Figure 19. Global Autoimmune and Inflammatory Immunomodulators Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 20. Global Autoimmune and Inflammatory Immunomodulators Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Autoimmune and Inflammatory Immunomodulators Sales Volume Share by Application (2021-2032) Figure 22. Global Autoimmune and Inflammatory Immunomodulators Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Autoimmune and Inflammatory Immunomodulators Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application (2021-2032) Figure 25. Global Autoimmune and Inflammatory Immunomodulators Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 26. Global Autoimmune and Inflammatory Immunomodulators Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Autoimmune and Inflammatory Immunomodulators Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Autoimmune and Inflammatory Immunomodulators Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Autoimmune and Inflammatory Immunomodulators Sales Value (2021-2032) & (US$ Million) Figure 30. North America Autoimmune and Inflammatory Immunomodulators Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Autoimmune and Inflammatory Immunomodulators Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Autoimmune and Inflammatory Immunomodulators Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Autoimmune and Inflammatory Immunomodulators Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Autoimmune and Inflammatory Immunomodulators Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Autoimmune and Inflammatory Immunomodulators Sales Value (2021-2032) & (US$ Million) Figure 36. South America Autoimmune and Inflammatory Immunomodulators Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Autoimmune and Inflammatory Immunomodulators Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Autoimmune and Inflammatory Immunomodulators Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Autoimmune and Inflammatory Immunomodulators Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Autoimmune and Inflammatory Immunomodulators Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Biologics
  • Small Molecules
Applications
  • Rheumatoid Arthritis
  • IBD
Companies covered
  • Johnson & Johnson
  • Eli Lilly
  • Pfizer
  • Amgen
  • AbbVie
  • AstraZeneca
  • Gilead Sciences
  • F. Hoffmann-La Roche
  • Enlivex Therapeutics
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Biogen Idec
  • Avaxia Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Autoimmune and Inflammatory Immunomodulators Sales Value (2021-2032)
  4. 1.2.2 Global Autoimmune and Inflammatory Immunomodulators Sales Volume (2021-2032)
  5. 1.2.3 Global Autoimmune and Inflammatory Immunomodulators Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Autoimmune and Inflammatory Immunomodulators Market Dynamics
  1. 2.1 Autoimmune and Inflammatory Immunomodulators Industry Trends
  2. 2.2 Autoimmune and Inflammatory Immunomodulators Industry Drivers
  3. 2.3 Autoimmune and Inflammatory Immunomodulators Industry Opportunities and Challenges
  4. 2.4 Autoimmune and Inflammatory Immunomodulators Industry Restraints
3 Autoimmune and Inflammatory Immunomodulators Market by Company
  1. 3.1 Global Autoimmune and Inflammatory Immunomodulators Company Revenue Ranking in 2025
  2. 3.2 Global Autoimmune and Inflammatory Immunomodulators Revenue by Company (2021-2026)
  3. 3.3 Global Autoimmune and Inflammatory Immunomodulators Sales Volume by Company (2021-2026)
  4. 3.4 Global Autoimmune and Inflammatory Immunomodulators Average Price by Company (2021-2026)
  5. 3.5 Global Autoimmune and Inflammatory Immunomodulators Company Ranking (2024-2026)
  6. 3.6 Global Autoimmune and Inflammatory Immunomodulators Company Manufacturing Base and Headquarters
  7. 3.7 Global Autoimmune and Inflammatory Immunomodulators Company Product Type and Application
  8. 3.8 Global Autoimmune and Inflammatory Immunomodulators Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Autoimmune and Inflammatory Immunomodulators Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Autoimmune and Inflammatory Immunomodulators Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Autoimmune and Inflammatory Immunomodulators Market by Type
  1. 4.1 Autoimmune and Inflammatory Immunomodulators Type Introduction
  2. 4.1.1 Biologics
  3. 4.1.2 Small Molecules
  4. 4.2 Global Autoimmune and Inflammatory Immunomodulators Sales Volume by Type
  5. 4.2.1 Global Autoimmune and Inflammatory Immunomodulators Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Autoimmune and Inflammatory Immunomodulators Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Autoimmune and Inflammatory Immunomodulators Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Autoimmune and Inflammatory Immunomodulators Sales Value by Type
  9. 4.3.1 Global Autoimmune and Inflammatory Immunomodulators Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Autoimmune and Inflammatory Immunomodulators Sales Value by Type (2021-2032)
  11. 4.3.3 Global Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type (2021-2032)
5 Autoimmune and Inflammatory Immunomodulators Market by Application
  1. 5.1 Autoimmune and Inflammatory Immunomodulators Application Introduction
  2. 5.1.1 Rheumatoid Arthritis
  3. 5.1.2 IBD
  4. 5.2 Global Autoimmune and Inflammatory Immunomodulators Sales Volume by Application
  5. 5.2.1 Global Autoimmune and Inflammatory Immunomodulators Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Autoimmune and Inflammatory Immunomodulators Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Autoimmune and Inflammatory Immunomodulators Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Autoimmune and Inflammatory Immunomodulators Sales Value by Application
  9. 5.3.1 Global Autoimmune and Inflammatory Immunomodulators Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Autoimmune and Inflammatory Immunomodulators Sales Value by Application (2021-2032)
  11. 5.3.3 Global Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application (2021-2032)
6 Autoimmune and Inflammatory Immunomodulators Regional Sales and Value Analysis
  1. 6.1 Global Autoimmune and Inflammatory Immunomodulators Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Autoimmune and Inflammatory Immunomodulators Sales by Region (2021-2032)
  3. 6.2.1 Global Autoimmune and Inflammatory Immunomodulators Sales by Region: 2021-2026
  4. 6.2.2 Global Autoimmune and Inflammatory Immunomodulators Sales by Region (2027-2032)
  5. 6.3 Global Autoimmune and Inflammatory Immunomodulators Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Autoimmune and Inflammatory Immunomodulators Sales Value by Region (2021-2032)
  7. 6.4.1 Global Autoimmune and Inflammatory Immunomodulators Sales Value by Region: 2021-2026
  8. 6.4.2 Global Autoimmune and Inflammatory Immunomodulators Sales Value by Region (2027-2032)
  9. 6.5 Global Autoimmune and Inflammatory Immunomodulators Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Autoimmune and Inflammatory Immunomodulators Sales Value (2021-2032)
  12. 6.6.2 North America Autoimmune and Inflammatory Immunomodulators Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Autoimmune and Inflammatory Immunomodulators Sales Value (2021-2032)
  15. 6.7.2 Europe Autoimmune and Inflammatory Immunomodulators Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Autoimmune and Inflammatory Immunomodulators Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Autoimmune and Inflammatory Immunomodulators Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Autoimmune and Inflammatory Immunomodulators Sales Value (2021-2032)
  21. 6.9.2 South America Autoimmune and Inflammatory Immunomodulators Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Autoimmune and Inflammatory Immunomodulators Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Autoimmune and Inflammatory Immunomodulators Sales Value Share by Country, 2025 VS 2032
7 Autoimmune and Inflammatory Immunomodulators Country-level Sales and Value Analysis
  1. 7.1 Global Autoimmune and Inflammatory Immunomodulators Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Autoimmune and Inflammatory Immunomodulators Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Autoimmune and Inflammatory Immunomodulators Sales by Country (2021-2032)
  4. 7.3.1 Global Autoimmune and Inflammatory Immunomodulators Sales by Country (2021-2026)
  5. 7.3.2 Global Autoimmune and Inflammatory Immunomodulators Sales by Country (2027-2032)
  6. 7.4 Global Autoimmune and Inflammatory Immunomodulators Sales Value by Country (2021-2032)
  7. 7.4.1 Global Autoimmune and Inflammatory Immunomodulators Sales Value by Country (2021-2026)
  8. 7.4.2 Global Autoimmune and Inflammatory Immunomodulators Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Autoimmune and Inflammatory Immunomodulators Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Autoimmune and Inflammatory Immunomodulators Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Autoimmune and Inflammatory Immunomodulators Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson
  2. 8.1.1 Johnson & Johnson Company Information
  3. 8.1.2 Johnson & Johnson Business Overview
  4. 8.1.3 Johnson & Johnson Autoimmune and Inflammatory Immunomodulators Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson Autoimmune and Inflammatory Immunomodulators Product Portfolio
  6. 8.1.5 Johnson & Johnson Recent Developments
  7. 8.2 Eli Lilly
  8. 8.2.1 Eli Lilly Company Information
  9. 8.2.2 Eli Lilly Business Overview
  10. 8.2.3 Eli Lilly Autoimmune and Inflammatory Immunomodulators Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly Autoimmune and Inflammatory Immunomodulators Product Portfolio
  12. 8.2.5 Eli Lilly Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Autoimmune and Inflammatory Immunomodulators Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Autoimmune and Inflammatory Immunomodulators Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 Amgen
  20. 8.4.1 Amgen Company Information
  21. 8.4.2 Amgen Business Overview
  22. 8.4.3 Amgen Autoimmune and Inflammatory Immunomodulators Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Amgen Autoimmune and Inflammatory Immunomodulators Product Portfolio
  24. 8.4.5 Amgen Recent Developments
  25. 8.5 AbbVie
  26. 8.5.1 AbbVie Company Information
  27. 8.5.2 AbbVie Business Overview
  28. 8.5.3 AbbVie Autoimmune and Inflammatory Immunomodulators Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 AbbVie Autoimmune and Inflammatory Immunomodulators Product Portfolio
  30. 8.5.5 AbbVie Recent Developments
  31. 8.6 AstraZeneca
  32. 8.6.1 AstraZeneca Company Information
  33. 8.6.2 AstraZeneca Business Overview
  34. 8.6.3 AstraZeneca Autoimmune and Inflammatory Immunomodulators Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca Autoimmune and Inflammatory Immunomodulators Product Portfolio
  36. 8.6.5 AstraZeneca Recent Developments
  37. 8.7 Gilead Sciences
  38. 8.7.1 Gilead Sciences Company Information
  39. 8.7.2 Gilead Sciences Business Overview
  40. 8.7.3 Gilead Sciences Autoimmune and Inflammatory Immunomodulators Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Gilead Sciences Autoimmune and Inflammatory Immunomodulators Product Portfolio
  42. 8.7.5 Gilead Sciences Recent Developments
  43. 8.8 F. Hoffmann-La Roche
  44. 8.8.1 F. Hoffmann-La Roche Company Information
  45. 8.8.2 F. Hoffmann-La Roche Business Overview
  46. 8.8.3 F. Hoffmann-La Roche Autoimmune and Inflammatory Immunomodulators Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 F. Hoffmann-La Roche Autoimmune and Inflammatory Immunomodulators Product Portfolio
  48. 8.8.5 F. Hoffmann-La Roche Recent Developments
  49. 8.9 Enlivex Therapeutics
  50. 8.9.1 Enlivex Therapeutics Company Information
  51. 8.9.2 Enlivex Therapeutics Business Overview
  52. 8.9.3 Enlivex Therapeutics Autoimmune and Inflammatory Immunomodulators Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Enlivex Therapeutics Autoimmune and Inflammatory Immunomodulators Product Portfolio
  54. 8.9.5 Enlivex Therapeutics Recent Developments
  55. 8.10 Bristol-Myers Squibb
  56. 8.10.1 Bristol-Myers Squibb Company Information
  57. 8.10.2 Bristol-Myers Squibb Business Overview
  58. 8.10.3 Bristol-Myers Squibb Autoimmune and Inflammatory Immunomodulators Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Bristol-Myers Squibb Autoimmune and Inflammatory Immunomodulators Product Portfolio
  60. 8.10.5 Bristol-Myers Squibb Recent Developments
  61. 8.11 Boehringer Ingelheim
  62. 8.11.1 Boehringer Ingelheim Company Information
  63. 8.11.2 Boehringer Ingelheim Business Overview
  64. 8.11.3 Boehringer Ingelheim Autoimmune and Inflammatory Immunomodulators Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Boehringer Ingelheim Autoimmune and Inflammatory Immunomodulators Product Portfolio
  66. 8.11.5 Boehringer Ingelheim Recent Developments
  67. 8.12 Biogen Idec
  68. 8.12.1 Biogen Idec Company Information
  69. 8.12.2 Biogen Idec Business Overview
  70. 8.12.3 Biogen Idec Autoimmune and Inflammatory Immunomodulators Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Biogen Idec Autoimmune and Inflammatory Immunomodulators Product Portfolio
  72. 8.12.5 Biogen Idec Recent Developments
  73. 8.13 Avaxia Biologics
  74. 8.13.1 Avaxia Biologics Company Information
  75. 8.13.2 Avaxia Biologics Business Overview
  76. 8.13.3 Avaxia Biologics Autoimmune and Inflammatory Immunomodulators Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Avaxia Biologics Autoimmune and Inflammatory Immunomodulators Product Portfolio
  78. 8.13.5 Avaxia Biologics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Autoimmune and Inflammatory Immunomodulators Value Chain Analysis
  2. 9.1.1 Autoimmune and Inflammatory Immunomodulators Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Autoimmune and Inflammatory Immunomodulators Sales Mode & Process
  6. 9.2 Autoimmune and Inflammatory Immunomodulators Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Autoimmune and Inflammatory Immunomodulators Distributors
  9. 9.2.3 Autoimmune and Inflammatory Immunomodulators Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst